DSM-Firmenich opened a new Jakarta office and expanded its Karawang manufacturing facility in Indonesia to boost production capacity and local innovation for flavors, fragrances, and nutrition. The pr
DSM-Firmenich initiated patent infringement litigation in China against multiple entities regarding unauthorized sclareol production. The company seeks court orders to cease infringement and secure co
DSM-Firmenich reported a 6% drop in Q1 adjusted EBITDA and 3% sales decline due to currency effects, yet maintained full-year guidance citing robust underlying volumes in perfumery and beauty segments
DSM-Firmenich reported Q1 core profit matching forecasts, with adjusted EBITDA reaching €434 million. Strong demand for perfumery and beauty products drove the results.
DSM-Firmenich China President Zhou Tao outlines the company's "15th Five-Year Plan" strategy, highlighting new investments in fermentation and fragrance facilities to meet growing demand in nutrition
DSM-Firmenich forecasts higher margins and organic growth for 2026, factoring in current economic challenges while assuming no prolonged impact from the Middle East conflict.
DSM-Firmenich reported a decline in Q4 sales driven by negative currency impacts despite organic growth, with a full-year outlook scheduled for release in March 2026.
CVC Capital Partners agreed to purchase DSM-Firmenich's animal nutrition and health business for €2.2 billion, finalizing the company's shift toward consumer-facing nutrition, health, and beauty opera
DSM-Firmenich and Korea’s ASTech have forged a partnership to advance the global UV filters market by establishing a stable supply chain for UV filter ingredients.
DSM-Firmenich completed its €1.08 billion share buyback for capital reduction, cutting issued shares by 4.5% in Q1 2026.
DSM-Firmenich missed Q3 estimates and trimmed guidance due to currency effects, reporting a 5% YoY revenue decline despite 2% organic growth supported by self-help programs.
ChemBrief